# A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)

> **NCT00414050** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1718 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Modified Process Hepatitis B Vaccine (Experimental)
- **BIOLOGICAL:** Hepatitis B Vaccine (Recombinant)
- **BIOLOGICAL:** Hepatitis B Vaccine (Recombinant)

## Key facts

- **NCT ID:** NCT00414050
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-06
- **Primary completion:** 2007-10-22
- **Final completion:** 2007-10-24
- **Target enrollment:** 1718 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00414050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00414050, "A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00414050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*